Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Brock

Showing results (51-60 of 194) with videos related to

Pageof 20
Sort By:
Arzneimittel-Forschung|April 1, 1972
[Pharmacology of 1,4-bis(3-(3,4,5-trimethoxybenzoyloxy)-propyl)-perhydro-1,4-diazepine (dilazep I.N.N.), a new coronary active substance]D Lenke, N Brock, H J Zechel
Arzneimittel-Forschung|April 1, 1972
[Toxicology of dilazep, a new coronary active agent]H H Abel, N Brock, D Lenke
BMC Bioinformatics|December 22, 2019
BayesMetab: treatment of missing values in metabolomic studies using a Bayesian modeling approachJasmit Shah, Guy N Brock, Jeremy Gaskins
Journal of Cancer Research and Clinical Oncology|January 1, 1989
Experimental investigations into the carcinogenic effect of antitumor and immunosuppressive agentsN Brock, B Schneider, J Stekar, et al.
Archives of Otolaryngology--Head & Neck Surgery|November 1, 1990
Pathologic quiz case 2. Invasive Alternaria alternataS R Schoem, A L Morton, N Brock
Arzneimittel-Forschung|October 1, 1973
[Quality test of different standard diets in breeding and rearing of rats and mice. Summarized compilation of biometric evaluation]N Brock, F Knappen, W Wilk, et al.
Urologia Internationalis|January 1, 1987
Electron microscopic investigations of the cyclophosphamide-induced lesions of the urinary bladder of the rat and their prevention by mesnaH Themann, E Oberdorf, N Brock, et al.
Methods and Findings in Experimental and Clinical Pharmacology|January 1, 1981
[Pharmacokinetics of Uromitexan]J Pohl, N Brock, B Schneider, et al.
Plos One|October 4, 2019
Use of rapid Model for End-Stage Liver Disease (MELD) increases for liver transplant registrant prioritization after MELD-Na and Share 35, an evaluation using data from the United Network for Organ SharingGuy N Brock, Kenneth Washburn, Michael R Marvin
European Journal of Cancer & Clinical Oncology|December 1, 1982
Studies on the urotoxicity of oxazaphosphorine cytostatics and its prevention--III. Profile of action of sodium 2-mercaptoethane sulfonate (mesna)N Brock, J Pohl, J Stekar, et al.
Pageof 20

Showing results (51-60 of 194) with videos related to

Sort By:
Pageof 20
Arzneimittel-Forschung|April 1, 1972
[Pharmacology of 1,4-bis(3-(3,4,5-trimethoxybenzoyloxy)-propyl)-perhydro-1,4-diazepine (dilazep I.N.N.), a new coronary active substance]D Lenke, N Brock, H J Zechel
Arzneimittel-Forschung|April 1, 1972
[Toxicology of dilazep, a new coronary active agent]H H Abel, N Brock, D Lenke
BMC Bioinformatics|December 22, 2019
BayesMetab: treatment of missing values in metabolomic studies using a Bayesian modeling approachJasmit Shah, Guy N Brock, Jeremy Gaskins
Journal of Cancer Research and Clinical Oncology|January 1, 1989
Experimental investigations into the carcinogenic effect of antitumor and immunosuppressive agentsN Brock, B Schneider, J Stekar, et al.
Archives of Otolaryngology--Head & Neck Surgery|November 1, 1990
Pathologic quiz case 2. Invasive Alternaria alternataS R Schoem, A L Morton, N Brock
Arzneimittel-Forschung|October 1, 1973
[Quality test of different standard diets in breeding and rearing of rats and mice. Summarized compilation of biometric evaluation]N Brock, F Knappen, W Wilk, et al.
Urologia Internationalis|January 1, 1987
Electron microscopic investigations of the cyclophosphamide-induced lesions of the urinary bladder of the rat and their prevention by mesnaH Themann, E Oberdorf, N Brock, et al.
Methods and Findings in Experimental and Clinical Pharmacology|January 1, 1981
[Pharmacokinetics of Uromitexan]J Pohl, N Brock, B Schneider, et al.
Plos One|October 4, 2019
Use of rapid Model for End-Stage Liver Disease (MELD) increases for liver transplant registrant prioritization after MELD-Na and Share 35, an evaluation using data from the United Network for Organ SharingGuy N Brock, Kenneth Washburn, Michael R Marvin
European Journal of Cancer & Clinical Oncology|December 1, 1982
Studies on the urotoxicity of oxazaphosphorine cytostatics and its prevention--III. Profile of action of sodium 2-mercaptoethane sulfonate (mesna)N Brock, J Pohl, J Stekar, et al.
Pageof 20